An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury

Trial Profile

An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs CXA 10 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions
  • Sponsors Complexa
  • Most Recent Events

    • 12 Nov 2015 According to Complexa media release, results were presented at the American Society of Nephrology's Kidney Week 2015.
    • 12 Nov 2015 According to Complexa media release, status changed from recruiting to completed.
    • 03 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top